The complement C5 inhibitor Ultomiris (ravulizumab) from AstraZeneca (LON:AZN) has won approval in Europe as adjunctive therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.  The regulatory nod represents the first approval for a long-acting C5 complement inhibitor for treating gMG in Europe.  While myasthenia gravis is a chronic…